Reports

First approvals of similar biotherapeutics in seven Latin American countries

Home/Reports | Posted 16/01/2024

In their review, Machado and colleagues examine the transparency and regulatory guidelines pertaining to the licensing of biosimilars, as well as the count of biosimilars granted approval by 13 medicines regulatory authorities [1].

Biosimilar terminology: insights from seven Latin American countries

Home/Reports | Posted 05/12/2023

In a review by Machado et.al., the authors examine the transparency and guidelines for biosimilars licensing and the number of biosimilars approved by 13 medicines regulatory authorities. In this context, we focused the discussion on seven Latin American countries: Argentina, Brazil, Chile, Colombia, Guatemala, Mexico and Peru as part of the broader review [1].

Biopharmaceutical industry in Argentina in the 21st century

Home/Reports | Posted 31/10/2023

In the dynamic landscape of Latin America's pharmaceutical industry, Argentina stands out with its distinctive structure and policies that have shaped its biopharmaceutical sector. Over the course of this century, the biopharmaceutical industry in Argentina has emerged as a critical player in the country's healthcare sector. 

Emerging disparities in market concentration among biosimilars

Home/Reports | Posted 22/09/2023

Biosimilars are an essential element of sustainable healthcare systems, with significant potential contribution to competitive markets. However, there are still challenges to be faced; for instance, there is a growing trend of biosimilar development targeting a limited range of biologicals [1].

Biosimilars uptake rates in Europe and the UK

Home/Reports | Posted 08/09/2023

The rate of uptake of biosimilars has accelerated as stakeholders have become increasingly comfortable with these products [1]. However, the adoption of biosimilars is lower in regions experiencing low social and governmental trust [2, 3].

Non-medical switching of biologicals/biosimilars webinar: Canada, Europe and the US

Home/Reports | Posted 01/09/2023

Biosimilars are now key players in the global drugs market offering potentially more affordable treatment options with similar safety and efficacy. However, there are concerns about non-medical switching practices of originator biologicals/biosimilars in different regions. A webinar was held on 20 July 2022 to discuss non-medical switching practices and to explore the importance of safeguarding the physician–patient relationship [1].

Biosimilar development targets limited range of biologicals

Home/Reports | Posted 01/09/2023

During the Biosimilars Medicines Conference in May 2023, Mr Aurelio Arias from IQVIA delivered a presentation about the biosimilar void in Europe. He highlighted that while the uptake of biosimilars has accelerated, there is a growing disparity in market concentration for smaller biologicals [1].

Biopharmaceutical industry in Brazil in the 21st century

Home/Reports | Posted 18/08/2023

In Brazil, the approach of the Industrial Economic Complex of Health (Complexo Econômico-Industrial da Saúde, CEIS) has been adopted in the planning of policies related to the health economy. This involves the integration of health, industrial and innovative policies.

Biopharmaceutical industry in Argentina and Brazil: a 21st century perspective

Home/Reports | Posted 03/08/2023

The biopharmaceutical industries in Latin American countries have gained significant attention in recent years, with an important growth in Argentina and Brazil where the policies implemented have emphasized collaboration between the public and private sector.

Pharmaceutical companies in China manufacturing copy biologicals

Home/Reports | Posted 20/06/2023

The market for copy biologicals in China has significantly grown over the past decade. The government has been actively promoting the development and use of copy biologicals as a way to improve access to affordable health care. As a result, the number of pharmaceutical companies developing copy biologicals has also increased rapidly and is expected to continue to grow in the coming years.